Partnered with major investors, venture capital companies, and pharmaceutical companies across the U.S and Asia, we pooled together $4B funds to invest in heath technologies and products
Licensing is an alternative sources of revenue to fund their R&D and clinical operations. For biotech companies, being able to sign out-licensing agreements with a credible licensee in early stages of the company life cycle can have a significant impact.
Thousands of Chinese companies have turned to the United States for partnership. Given huge amount of capitals these companies are holding, U.S pharmaceutical company will benefit from such partnership if the partnership is well designed.